

For Immediate Release

Company Name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com>

Revision of Earnings Forecasts

Tokyo, Japan (July 29, 2011) –Daiichi Sankyo Company, Limited (“the Company”) today announced a revision of its earnings forecasts, which was announced on May 12, 2011, in light of recent trends in operating performance.

Revision of Earnings Forecasts

1. Revision of consolidated earnings forecasts for the first six months (cumulative) of the fiscal year ending March 2012

(From April 1, 2011 to September 30, 2011)

	Net sales	Operating income	Ordinary income	Net income	Net income per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecasts (A)	470,000	50,000	50,000	24,000	34.10
Revised forecasts (B)	470,000	60,000	60,000	35,000	49.72
Change (B-A)	0	10,000	10,000	11,000	
Percentage of change (%)	0.0	20.0	20.0	45.8	
(Reference) Results of the first six months of the previous fiscal year (FY2010)	498,886	90,107	92,647	52,154	74.09

2. Revision of consolidated earnings forecasts for the fiscal year ending March 2012

(From April 1, 2011 to March 31, 2012)

	Net sales	Operating income	Ordinary income	Net income	Net income per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecasts (A)	970,000	90,000	90,000	45,000	63.93
Revised forecasts (B)	970,000	90,000	90,000	50,000	71.03
Change (B-A)	0	0	0	5,000	
Percentage of change (%)	0.0	0.0	0.0	11.1	
(Reference) Results of the previous fiscal year (FY2010)	967,365	122,143	131,762	70,121	99.62

(Reason for the revision)

In consideration of the financial results of the first three months of FY2011, Daiichi Sankyo revises the forecasts of consolidated results for the first six months (cumulative) and full year of FY2011.

Net sales forecasts remains unchanged as the Group intends to off set the decline in sales from yen appreciation by expanding its mainstays and new products.

Both operating income and ordinary income for the first six months (cumulative) are upwardly revised by ¥10.0 billion respectively, due to the improvement in cost-to-sales ratio on the account of product composition, and expenses partially carried forward to the third quarter or later being affected by the earthquake and other factors. No revision is made on the annual forecasts.

Net income is upwardly revised by ¥11.0 billion for the first six months (cumulative) and by ¥5.0 billion for the full year period of FY2011, taking in consideration the revision in ordinary income, as well as reduced tax expenses at Ranbaxy Laboratories Ltd and gain on sales of underutilized real estate .

* The forecasted statements shown above are based on information currently available and certain assumptions that the Company regards as reasonable. Actual performance and other results may differ materially from these forecasted figures due to various factors.